The role of the fetal biophysical profile in the management of fetal growth restriction.

Doppler ultrasound biophysical profile fetal acidemia fetal death fetal growth restriction fetal hypoxemia fetal surveillance nonstress test

Journal

American journal of obstetrics and gynecology
ISSN: 1097-6868
Titre abrégé: Am J Obstet Gynecol
Pays: United States
ID NLM: 0370476

Informations de publication

Date de publication:
04 2022
Historique:
received: 16 10 2021
revised: 17 01 2022
accepted: 21 01 2022
entrez: 4 4 2022
pubmed: 5 4 2022
medline: 6 4 2022
Statut: ppublish

Résumé

Growth-restricted fetuses are at risk of hypoxemia, acidemia, and stillbirth because of progressive placental dysfunction. Current fetal well-being, neonatal risks following delivery, and the anticipated rate of fetal deterioration are the major management considerations in fetal growth restriction. Surveillance has to quantify the fetal risks accurately to determine the delivery threshold and identify the testing frequency most likely to capture future deterioration and prevent stillbirth. From the second trimester onward, the biophysical profile score correlates over 90% with the current fetal pH, and a normal score predicts a pH >7.25 with a 100% positive predictive value; an abnormal score on the other hand predicts current fetal acidemia with similar certainty. Between 30% and 70% of growth-restricted fetuses with a nonreactive heart rate require biophysical profile scoring to verify fetal well-being, and an abnormal score in 8% to 27% identifies the need for delivery, which is not suspected by Doppler findings. Future fetal well-being is not predicted by the biophysical profile score, which emphasizes the importance of umbilical artery Doppler and amniotic fluid volume to determine surveillance frequency. Studies with integrated surveillance strategies that combine frequent heart rate monitoring with biophysical profile scoring and Doppler report better outcomes and stillbirth rates of between 0% and 4%, compared with those between 8% and 11% with empirically determined surveillance frequency. The variations in clinical behavior and management challenges across gestational age are better addressed when biophysical profile scoring is integrated into the surveillance of fetal growth restriction. This review aims to provide guidance on biophysical profile scoring in the in- and outpatient management of fetal growth restriction.

Identifiants

pubmed: 35369904
pii: S0002-9378(22)00042-4
doi: 10.1016/j.ajog.2022.01.020
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

475-486

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Auteurs

Ahmet A Baschat (AA)

Department of Gynecology & Obstetrics, Johns Hopkins Center for Fetal Therapy, Johns Hopkins School of Medicine, Baltimore, MD. Electronic address: abascha1@jhmi.edu.

Henry L Galan (HL)

Division of Maternal-Fetal Medicine, Department of Obstetrics & Gynecology, Colorado Fetal Care Center, Children's Hospital of Colorado, University of Colorado School of Medicine, Aurora, CO.

Wesley Lee (W)

Division of Maternal-Fetal Medicine, Department of Obstetrics & Gynecology, Baylor College of Medicine, Houston, TX.

Greggory R DeVore (GR)

Department of Obstetrics & Gynecology, Fetal Diagnostic Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.

Giancarlo Mari (G)

Division of Maternal-Fetal Medicine, Department of Obstetrics & Gynecology, Women's Health Institute, Cleveland Clinic Foundation, Cleveland, OH.

John Hobbins (J)

Division of Maternal-Fetal Medicine, Department of Obstetrics & Gynecology, University of Colorado School of Medicine, Aurora, CO.

Anthony Vintzileos (A)

Division of Maternal-Fetal Medicine, Department of Obstetrics & Gynecology, NYU Long Island School of Medicine, New York, NY.

Lawrence D Platt (LD)

Center for Fetal Medicine and Women's Ultrasound and Department of Obstetrics and Gynecology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.

Frank A Manning (FA)

Fetal Maternal Medicine Consultant, Envision Health, Nashville, TN.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH